Phase I, open-label study was designed to investigate the pharmacokinetic, safety, and tolerability profiles of sofosbuvir and its metabolites (GS-556500 and GS-331007) after a single dose of sofosbuvir 400 mg and once daily dosing of sofosbuvir 400 mg for 7 days in healthy Chinese subjects
Latest Information Update: 12 Sep 2018
At a glance
- Drugs Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Gilead Sciences
- 12 Sep 2018 New trial record
- 02 Sep 2018 Results published in the Clinical Therapeutics